100 results about "Cell Proliferative Activity" patented technology

IL-10 sequence variants are disclosed that retain the therapeutically desirable anti-inflammatory properties of wild-type IL-10 but do not retain the hemoatopoeitic cell regulatory and cell proliferative activities. The mutant IL-10 polypeptides of the invention are used in methods of treating diseases involving inflammatory response, including neuropathic pain and other neurological disorders.

The invention discloses a type of amino acid modified curcumin, a synthesis method thereof, and an application thereof. According to the invention, structural modification is carried out upon curcumin by using natural amino acid, such that 1-(4-hydroxy-3-methoxyphenyl)-7-(4-oxyacetyl amino carbobenzoxy-3-methoxyphenyl)-1,6-heptadiene-3,5-diketone which is represented by a general formula (I) is obtained. With an MTT method, evaluation is carried out upon the compound represented by the general formula (I) in the inhabitance of proliferation activities of four cells which are K562, H22, HL60 and S180. IC50 values of the compound represented by the general formula (I) in inhibiting the proliferations of the four tumor cells are calculated. As a result of experiments, with the compound represented by the general formula (I), proliferations of tumor cells can be substantially inhibited. The compound has excellent anti-tumor activity, and can be prepared into anti-tumor medicines.

IL-10 sequence variants are disclosed that retain the therapeutically desirable anti-inflammatory properties of wild-type IL-10 but do not retain the hemoatopoeitic cell regulatory and cell proliferative activities. The mutant IL-10 polypeptides of the invention are used in methods of treating diseases involving inflammatory response, including neuropathic pain and other neurological disorders.

The present invention provides novel azepane derivatives or pharmaceutically acceptable salts thereof according to the general formula (I) and their preparation methods, wherein the remaining symbols have the meanings given in the description. The compounds according to the invention have anti-proliferative activity and show increased plasma stability.

The invention relates to a novel ingenane-type diterpenoid (1) and a tiglic alkane-type diterpenoid (2) obtained by separating from euphorbia stracheyi, and two ingenane-type diterpenoids (3, 4) obtained by separating from ewuphorbia wallichii, as well as a preparation method of the same, and an application of the ingenane-type diterpenoid (1) and a tiglic alkane-type diterpenoid (2) in preparation for anti-tumour medicines. In-vitro anti-tumour active screening indicates that the compounds disclosed by the invention are obvious in the effect of inhibiting tumour cell proliferative activity, and are capable of being combined with pharmaceutically acceptable carriers to prepare clinically acceptable medicine dosage forms for treating various cancers. The invention provides lead compounds for researching novel anti-tumour medicines, and has an important value in development and utilization for the resources of medicinal plants.

An anti-infectious immunopotentiator for pig, ox, yak, etc is prepared through artificially synthesizing the CpG oligonucleotide sequce able to excite the reproductive activity of immune cell, preparing the chitosan nanoparticles from deacetyl chitosan, and using said chitosan nanoparticles for molecular packaging of CpG oligonucleotide. It can be used to immunize the experimental animal by intramuscular injection or oral applialtion.

The invention discloses an N-alkyl-1,2,3,4,5,6-hexahydro-1,1,5,5-tetramethyl-7H-2,4 alpha-methanonaphthalene-7-amine compound as well as a synthetic method and an application thereof. Longifolene serving as a heavy oil main component is relatively rich terpenoid in numerous natural extracts. The synthetic method comprises the following steps: obtaining isolongifolene through longifolene isomerization, obtaining isolongifolenone through allylic oxidation of the isolongifolene, carrying out dehydration condensation on the isolongifolenone and primary amine so as to obtain imine and obtaining the chiral N-alkyl-1,2,3,4,5,6-hexahydro-1,1,5,5-tetramethyl-7H-2,4 alpha-methanonaphthalene-7-amine compound after reduction. The compound has vey good inhibition activity on candida albicans, aspergillus niger, candida tropicalis, escherichia coli, staphylococcus aureus, pseudomonas fluorescens, bacillus subtilis and the like, a part of compound has good cancer cell proliferation inhibition activity on human breast cancer cells MCF-7, human lung adenocarcinoma cells A549, hepatoma cells HepG2 and SMMC-7721, and the N-alkyl-1,2,3,4,5,6-hexahydro-1,1,5,5-tetramethyl-7H-2,4 alpha-methanonaphthalene-7-amine compound is a potential antibacterial and bactericidal and anti-tumor compound.

A method for preparing primary cell dental pulp stem construction and method of dental pulp stem cell library, the use of thermostatic shaker at specific temperature and speed conditions, can be in a few minutes after digestion, to extract enough has good biological activity of dental pulp stem cells, which can shorten the primary dental pulp stem cells generation of extraction time, save time and cost, large scale production can be obtained at the same time, plenty of pulp stem cells, can meet the requirements of dental pulp stem cells in stem cell library and later stem cells for clinical treatment and regenerative medicine research needs, and the pulp tissue under conventional semi digested 30min or full digestion 1H control group compared to the amount of DPSCs had no significant difference, but the cell proliferation activity was significantly higher than the control group. Therefore, this method can be carried out quickly in batches in the construction of DPSCs library, which shortens the time of DPSCs primary extraction, saves time and cost, and is suitable for large-scale production.

The invention belongs to the field of biology, and particularly relates to a nucleotide sequence of a recombinant fibronectin mutant and application of the recombinant fibronectin mutant. According tothe recombinant fibronectin mutant provided by the invention, a structural domain for promoting cell adhesion and cell proliferation on fibronectin is selected, the nucleotide sequence for coding therecombinant fibronectin mutant is designed by utilizing a translation pause theory, and under the condition of unchanging an amino acid sequence of the recombinant fibronectin, the recombinant fibronectin is obtained by replacing a codon with a higher translation speed in the last 20 codons of the recombinant fibronectin with a codon with a lower translation speed. The recombinant fibronectin mutant provided by the invention is simple in purification process and can promote cell proliferation activity and adhesion activity.

The invention belongs to the technical field of medicament synthesis and in particular relates to synthesis of tetrahydroisoquinoline compounds and initial application of the tetrahydroisoquinoline compounds in inhibiting tumor cell proliferation. Through the modification of a structure of natural (-)-alpha-(1R,9S)-narcotine, a series of novel tetrahydroisoquinoline compounds (I) are synthesized. Through the screening of anti-tumor activity in vitro, the novel tetrahydroisoquinoline compounds have remarkable effect of inhibiting the tumor cell proliferation activity and can be further developed into a novel anti-tumor medicament.

This invention is to provide a means capable of obtaining excellent cell proliferation activity without depending on a thickness of a coating layer in a technique of coating a cell culture substrate (cell culture vessel) using a polymer. Provided is a cell culture substrate comprising a coating layer on at least one surface of a polymer substrate, wherein the coating layer includes a copolymer comprising more than 40% by mole and less than 100% by mole of a structural unit (1) derived from carboxyalkyl (meth)acrylate represented by Formula (1) and more than 0% by mole and less than 60% by mole of a structural unit (2) derived from ethylenically unsaturated monomer having a hydroxyl group (the total of the structural unit (1) and the structural unit (2) is 100% by mole).

The invention relates to a preparation method of FGF1 sericin protein gel with activity for promoting cell proliferation and a product thereof. The preparation method comprises the following steps that sericin protein containing human FGF1 protein is extracted by human FGF1 gene modifying silk, and a sericin protein solution containing human FGF1 protein is obtained; after renaturation, an FGF1 sericin protein aqueous solution is obtained after dialysis with water, and FGF1 sericin protein hydrogel is obtained by centrifugation; and the FGF1 sericin protein hydrogel is placed at 4 DEG C, an FGF1 sericin protein gel material is formed by cross-linking of a chemical cross-linking agent or inducement of an inducer. The prepared gel material has the activity of promoting cell proliferation andhas broad application potential in tissue engineering.

The invention discloses gynostemma pentaphyllum extract compounds (I) with inhibiting actions on human liver cancer HepG2 cells and a preparation method thereof, and application of the compounds in medicine, belonging to the field of phytochemistry. The preparation method of the compounds disclosed as Formula (I) comprises the following steps: carrying out high-temperature high-pressure treatment on whole gynostemma pentaphyllum, extracting with ethanol under reflux, and concentrating the extracting solution under reduced pressure to obtain an extractum; adding distilled water into the extractum to form a suspensoid, and extracting sequentially with dichloromethane and ethyl acetate; concentrating under reduced pressure to obtain an ethyl acetate extract; passing the extract through an HP20 resin, eluting sequentially with 20%, 50% and 70% ethanol, and concentrating the 70% ethanol eluate under reduced pressure to obtain an elution product; and treating the elution product with silica gel column chromatography, eluting with dichloromethane / methanol in a ratio of 20:1-10:1 (v / v), sectionally collecting the eluates to obtain 6 components, and eluting the component 3 with acetonitrile / water in a ratio of 53:47 (v / v) at the flow rate of 3 mL / minute in a semipreparative chromatographic column (250*10mm, 5 mu m). The pharmacodynamical test indicates that the compounds disclosed as Formula (I) have obvious activities for inhibiting cancer cell proliferation.

The invention relates to a compound radix codonopsis total saponins and immunopolysaccharides nano emulsion composition and a preparation method thereof. The nano emulsion composition provided by the invention is an oil in water type nano emulsion, has particle sizes between 1nm and 100nm, and is prepared from the following ingredients of three traditional Chinese medicinal active ingredients (radix codonopsis total saponins, pachyman and a radix glycyrrhizae polysaccharide), a surfactant, a cosurfactant, an oil phase and distilled water. The preparation method of the nano emulsion provided by the invention is simple and feasible; a device is easy to control; the product quality is easy to control; the particle size of a liquid drop is small; the solubility and the stability of a medicine can be improved; the proliferation activity of a splenic lymphocyte of an immunocompromised mouse can be improved. The nano emulsion composition provided by the invention can be used for obviously improving the immunoregulatory activity of the three traditional Chinese medicinal active ingredients, and has the potential of developing an immunopotentiator, so as to promote the development and the utilization of a traditional Chinese medicinal resource and an active ingredient thereof.

The invention discloses a mouse primary hepatocyte perfusion type separating and in-vitro culturing method. The perfusion type separating of mouse primary hepatocytes is conduced through an in-situ living body perfusion method, a high-yield single-cell suspension can be obtained, and therefore a basis is provided for in-vitro long-time culturing of the primary hepatocytes. An applied stimulating culture solution contains mouse colony stimulating factors (CSF), mouse IL-2, mouse IL-6 and mouse recombinant hepatocyte growth factors r-mHGF and other cell factors; the primary hepatocytes can be separated through stimulation according to the reasonable ratio for in-vitro proliferation, and the number can reach 2.25 times the number of initially-added primary hepatocytes 72 hours later. The cellproliferation activity can be kept for at least 1-2 weeks under the in-vitro conditions, the problem that the primary hepatocytes cannot be cultured for a long time in vitro is solved, and thereforethe method can be used for infection of retroviruses, provides a basis for over-expression target genes or knockout target genes in in-vitro primary cells, and greatly expands the application field ofthe primary hepatocytes.

The invention discloses a coding sequence of a fibronectin mutant with high expression quantity and strong activity and application of the coding sequence. The coding sequence of the fibronectin mutant provided by the invention is as shown in SEQ ID NO. 1. The coding sequence is obtained by selecting an active structural domain for promoting cell proliferation and cell adhesion on fibronectin and replacing a codon with a relatively high translation speed in the last 30 codons of the recombinant fibronectin with a codon with a relatively low translation speed by utilizing a translation pause theory under the condition of not changing an amino acid sequence of the recombinant fibronectin. The coding sequence obviously promotes the soluble expression of the fibronectin mutant in escherichia coli. The fibronectin mutant is obtained by constructing a recombinant vector, expressing and purifying the coding sequence, and the function of promoting cell proliferation activity and adhesion activity is obviously improved.

The invention relates to a sesquiterpene lactone compound, a pharmaceutical composition comprising the sesquiterpene lactone compound, a preparation method and the application of the sesquiterpene lactone compound, new sesquiterpene lactone 1 and new sesquiterpene lactone 2 separated from Inula Britannica, the preparation method for the new sesquiterpene lactone 1 and new sesquiterpene lactone 2, and the application of the new sesquiterpene lactone 1 and new sesquiterpene lactone 2 in preparation of an anti-tumor medicament. In-vitro anti-tumor activity screening shows that the compound disclosed by the invention has obvious activity on inhibiting the proliferation of tumor cells, can be made into clinically acceptable medicinal agents by combining with pharmaceutically acceptable carriers, and is used for treating cancer. The invention provides a lead compound for developing a new antitumor medicament, and has an important value on developing the resources of medicinal plants.

The invention discloses a protein sericin gel based on transformation of human platelet derived growth factor (PDGF-BB) gene silk and a preparation method and application of the protein sericin gel. By using the functional silk of the human-derived PDGF-BB, sericin with the active PDGF-BB protein is extracted, a gelling reaction of the sericin is induced at the low temperature, the prepared protein sericin gel is good in mechanical property, degradable and good in cell compatibility and does not have toxicity, the PDGF-BB can stably exist, apoptosis cannot be caused, the obvious cellular inflammatory response cannot be caused, and the sericin gel biological material with a function of improving the cell proliferation activity can be applied to the tissue engineering.

The invention relates to a preparation method and a product of a sericin-agarose composite gel having the activity of promoting cell proliferation and a product, sericin of recombinant FGF1 protein and FGF2 protein can be extracted from transgenic human FGF1 gene and human FGF2 gene silk, a sericin solution containing the recombinant FGF1 protein and the FGF2 protein is obtained, the sericin solution containing the recombinant FGF1 protein and the FGF2 protein is renatured to obtain a renatured sericin solution containing the recombinant FGF1 protein and the FGF2 protein, the renatured sericinsolution and an agarose solution are mixed for injection molding and molding to obtain the sericin-agarose composite gel having the activity of promoting cell proliferation, and the prepared composite gel has good stability, can better support the proliferation and growth of NIH3T3 cells, and has low cytotoxicity, and has broad application prospects in tissue engineering.

The invention discloses application of hematoxylin in measuring the attached cell multiplication activity and the toxic effect of a medicine to attached cells. In the invention, hematoxylin is utilized to dye cells, and then the absorbency value under a specific wavelength is measured, so that corresponding data and conclusions are obtained. The results of measuring the cell multiplication activity of different time phases (12h, 24h, 48h and 72h) of attached cells, such as SGC7901, M21, Huvec and the like for many times by the inventor through adopting a hematoxylin dyeing method all indicate that the method not only has high specificity but also has better repeatability, and CV is less than 3%. The invention has the advantages of high sensitivity, stable detection result, wide application range, low cost and the like.

The invention discloses a triazole gold compound as well as a preparation method and application thereof. The structural general formula of the compound is shown as the description, wherein R1 is phenyl, p-methylphenyl, p-Chlorophenyl, a methoxyl group, methoxycarbonyl or p-fluorophenyl; R2 is triphenylphosphine, dimethyl -phenyl phosphine, 35 fluorine Phenyl phosphine or triethylphosphine; R3 is hydrogen, methyl or phenyl; R4 is hydrogen, methyl or phenyl; X is boron tetrafluoride negative ions or trifluoromethyl sulfonic acid negative ions. The inhibitory activity IC50 of the triazole gold compound disclosed by the invention (in nanomoles) indicates that the triazole gold compound is strongly combined with thioredoxin reductase active centers. The triazole gold compound disclosed by the invention has high anticellularity reproductive activity, is a thioredoxin reductase inhibitor adopting a novel structure, is good in physico-chemical property, is good in water solubility, and can be utilized as a lead compound of antitumor drugs.

The invention discloses a combined drug for treating colorectal cancer. The combined drug is prepared from diosgenin, baicalein A, fucoidan and psoralen. An in-vivo animal experiment shows that the combination application of the diosgenin, the baicalein A, the fucoidan, the psoralen, Binimetinib and cetuximab has a significant synergistic effect on the treatment of the colorectal cancer, the diosgenin can affect the blood supply of tumor by inhibiting the proliferation activity of endothelial cells, and finally inhibit the proliferation of a subcutaneous tumor model, meanwhile, the diosgenin can inhibit the metastasis of rectal cancer through the direct action, and has the synergistic interaction effect by combining with the cetuximab; and the purpose of tumor prevention can be achieved bythe psoralen through multiple mechanisms of calcium antagonistic effect, multi-drug resistance reversing effect, estrogen-like effect, photosensitive activity effect, apoptosis inducing , mitochondrial degeneration inducing and the like.

The invention provides a model for predicting cell proliferation activity by taking 87 genes as biomarkers. The expression level of the cell proliferation gene set is positively related to the proliferation activity of cells. The invention provides a method for evaluating cell proliferation activity without in-vitro culture. In combination with a single cell sequencing technology, the proliferation activity of each cell type in vivo can be rapidly, simply and conveniently determined. The invention can help people judge whether notably proliferated normal cells exist in cancer tissues or not. When a large number of cells exist in cancer tissues, treatment and evaluation means for cell proliferation markers are interfered and possibly fail; when a large number of cells do not exist in cancertissues, a treatment and evaluation means for the cell proliferation marker is expected to be successful. The method has auxiliary guiding significance for cancer diagnosis and treatment based on a cell proliferation mechanism.

The invention discloses a microvibration loading device for bone formation related cells. According to the device, the excitation end of an electromagnetic vibration exciter is in threaded connection with the bottom of a vibration cavity, and a microvibration box in which the bone formation related cells are accommodated is arranged in the vibration cavity; the cavity cover of the vibration cavity is positioned on the vibration cavity through a side positioning screw; the electromagnetic vibration exciter is electrically connected with an excitation control device; according to the excitation device, a singlechip controls a sine wave signal generator, and a power amplifier drives the electromagnetic vibration exciter; and control parameters are input and displayed by a display and input circuit. The device can perform microvibration loading on the bone formation related cells, stimulate the microvibration environment of the bone formation related cells to analyze the influence of microvibration on the proliferation activity and the functional state of the bone formation related cells of an interface, provides accurate and reliable experimental basis for design, manufacturing and implanting of an implant, ensures that the implant can be combined with the bone interface well, and improves the effects of treating and repairing the bone interface.

The invention discloses a method for targeted inhibition of infiltration and transfer of glioma cells, which includes targeted inhibition of JAM2 (junctional adhesion molecules 2) of the glioma cells. Experiments show that cell proliferative activity of the glioma cells can be inhibited in vivo by 30% by inhibition on the JAM2 of the glioma cells, cell migration activity can be inhibited by more than 80%. The method has superb clinical application prospect, and by the method, non-specificity of existing drug therapy on glioma cell cases, the defects in surgical therapy, radiotherapy, chemotherapy and endocrine therapy are overcome, and the range of targeted therapy is widened.

The invention discloses application of aripiprazole in preparation of an antineoplastic drug. According to the application, it is found for the first time that the aripiprazole can inhibit the proliferative activity of colorectal cancer cells, reduce the clone formation number of the colorectal cancer cells, and inhibit growth of tumors of colorectal cancer. The colorectal cancer proliferative activity inhibiting effect of the aripiprazole is more remarkable along with the increase of the concentration of the aripiprazole and prolonging of the medication time, and has concentration dependencyon the cycle arrest function and in-vivo inhibiting function on the colorectal cancer cells. Meanwhile, the aripiprazole is a drug ratified by FDA for sale; compared with new medicine development, thecost is low, no obvious toxic or side effect exists, the aripiprazole is used for assisting in treatment of colorectal cancer, and a new drug source can be provided for adjuvant therapy of cancer.

The invention discloses a fibronectin composition freeze-dried micro-core with a skin barrier repairing effect and a preparation method thereof. The freeze-dried micro-core is prepared from the following raw materials in percentage by weight: 10 to 15 ppm of fibronectin, 10 to 15 ppm of platelet-derived growth factors, 10 to 15 ppm of metallothionein type IV, 10 to 15 ppm of elastin, 20 to 40 ppm of fibroin, freeze-drying protection liquid and the balance of water. The pharmaceutical composition is a biological functional product, has cell proliferation promoting activity and cell migration promoting activity, shows the effect of relieving stabbing pain in lactic acid stabbing pain experiments, is free of preservatives and artificial chemical components during preparation, and is non-irritant to skin.

The invention discloses G1 / G0-phase blocked pentacyclic indol-quinolizidine which is (6S)-3-acetyl-6-(N-phenylacetyl amino acyl)-oxidative methyl-4,6,7,12-tetrahydro-4-oxoindole-[2,3-1] quinolizidine, and discloses a compound, cell proliferation resistance activity, antineoplastic activity and application thereof.

The invention discloses a heteroaromatic amide compound and a preparation method and application thereof. According to the heteroaryl amide compound provided by the invention, a preliminary activity research shows that the compound has selectivity to STAT3 and also has very strong tumor cell proliferation inhibition activity; the compound can be used as a series of novel STAT3 inhibitors and can be used for preparing drugs for treating corresponding diseases. The compound has obvious killing effect on human cancer cells, especially human breast cancer cell line MDA-MB-231, human prostate cancer cell line PC-3 and human prostate cancer cell line DU-145, has the potential of being prepared into novel antitumor drugs, and has better market prospect.